GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Gross Margin %

BNR (Burning Rock Biotech) Gross Margin % : 71.40% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Burning Rock Biotech's Gross Profit for the three months ended in Sep. 2024 was $12.98 Mil. Burning Rock Biotech's Revenue for the three months ended in Sep. 2024 was $18.18 Mil. Therefore, Burning Rock Biotech's Gross Margin % for the quarter that ended in Sep. 2024 was 71.40%.


The historical rank and industry rank for Burning Rock Biotech's Gross Margin % or its related term are showing as below:

BNR' s Gross Margin % Range Over the Past 10 Years
Min: 64.49   Med: 67.59   Max: 73.02
Current: 68.72


During the past 7 years, the highest Gross Margin % of Burning Rock Biotech was 73.02%. The lowest was 64.49%. And the median was 67.59%.

BNR's Gross Margin % is ranked better than
75.74% of 202 companies
in the Medical Diagnostics & Research industry
Industry Median: 47.865 vs BNR: 68.72

Burning Rock Biotech had a gross margin of 71.40% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Burning Rock Biotech was 0.10% per year.


Burning Rock Biotech Gross Margin % Historical Data

The historical data trend for Burning Rock Biotech's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech Gross Margin % Chart

Burning Rock Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 71.61 73.02 71.70 67.47 67.59

Burning Rock Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.35 64.51 68.21 70.42 71.40

Competitive Comparison of Burning Rock Biotech's Gross Margin %

For the Diagnostics & Research subindustry, Burning Rock Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burning Rock Biotech's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's Gross Margin % falls into.



Burning Rock Biotech Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Burning Rock Biotech's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=50.9 / 75.269
=(Revenue - Cost of Goods Sold) / Revenue
=(75.269 - 24.398) / 75.269
=67.59 %

Burning Rock Biotech's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=13 / 18.18
=(Revenue - Cost of Goods Sold) / Revenue
=(18.18 - 5.2) / 18.18
=71.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Burning Rock Biotech  (NAS:BNR) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Burning Rock Biotech had a gross margin of 71.40% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Burning Rock Biotech Gross Margin % Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Burning Rock Biotech Business Description

Traded in Other Exchanges
Address
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.